Clinical Pharmacology Considerations for Peptide Drug Products Guidance for Industry - DRAFT GUIDANCE
FDA-2023-D-3391-0028Other
Comments
2
Last activity Feb 9, 2024
Deadline
Closed on Dec 12, 2023
Closed Dec 12, 2023
Net supportiSupport minus oppose · campaigns included
—
Document
Details
The document's own metadata, straight from the source system.
- Title
- Clinical Pharmacology Considerations for Peptide Drug Products Guidance for Industry - DRAFT GUIDANCE
- Posted
- Dec 11, 2023
- Comment period
- Dec 11, 2023 – Dec 12, 2023
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 0 of 2 comments
0%· analysis in progress
Stance breakdown
—
Net support
Not yet analyzed2
Who commented
Breakdown by commenter type.
Not yet analyzed
2
Comments over time
Weekly arrivals, stacked by stance.
Posted Dec 11, 2023Deadline Dec 12, 2023
Dec 11Feb 5
Support0Oppose0Other0
Issues raised
The docket's canonical issues. Select one to browse its comments.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.